MedicYatra provides the safe & best Acute Hepatitis B treatment and procedure at its affiliate & trusted hospitals & clinics in various metro cities of India, like Mumbai, Delhi, Bangalore, Chennai, Pune etc.Our Associate Board certified doctors are extensively trained and vastly experienced and have performed hundreds of such cases at our state of the art JCI accredited hospitals & Clinics. Our aim is to provide you the best of the services at the most affordable costs. Don't forget to say hi at info@medicyatra.com
2. Email: enquiry@medicyatra.com
Epidemiology
Incidence declined in US from 1990 to
2005
70,000 acute Hepatitis B infections in US
in 2005
Risk factors: sexual exposure, IVDU
<5% of acute infections in
immunocompetent adults progress to
chronic hepatitis B
Copyright @ Forever Medic Online Pvt. Ltd
3. Email: enquiry@medicyatra.com
Clinical Manifestations
Incubation period 1-4 mos
Prodromal period w/ serum
sickness like symptoms
Then constitutional sx,
anorexia, nausea, jaundice
and RUQ discomfort
Only 30% develop icteric
hepatitis.
70% subclinical or anicteric
hepatitis.
More severe infections in
patients coinfected w/ other
hepatitis viruses or underlying
liver disease
Copyright @ Forever Medic Online Pvt. Ltd
4. Email: enquiry@medicyatra.com
Diagnosis
To diagnose acute infection: HBSAg + IgM anti-
HBc (also suggestive is +HBeAg)
Recovery: Normalization of ALT, disappearance
of HBV DNA, transition from HBSAg to anti-HBs
and transition from IgM anti-HBc to IGG
Chronic: persistence of HBSAg > 6 months
Copyright @ Forever Medic Online Pvt. Ltd
6. Email: enquiry@medicyatra.com
Laboratory Testing
Elevated transaminases-values up to
1000-2000 IU/L with ALT > AST
Serum bilirubin may be normal
Prothrombin time best indicator of
prognosis
Normalization of transaminases within 1-4
months in patients who recover
ALT elevated > 6 months indicates
progression to chronic hepatitis
Copyright @ Forever Medic Online Pvt. Ltd
7. Email: enquiry@medicyatra.com
Fulminant Hepatic Failure
rapid development of severe acute liver
injury with impaired synthetic function and
encephalopathy in a person who
previously had a normal liver or had well-
compensated liver disease
unusual in Hep B infections-occurs in 0.1
to 0.5% of pts
due to massive immune-mediated lysis of
infected hepatocytes
Copyright @ Forever Medic Online Pvt. Ltd
8. Email: enquiry@medicyatra.com
Treatment
mostly supportive
avoid interferon due to increased risk of
hepatic necroinflammation
consider antiviral therapy with lamivudine,
telbivudine, adefovir, or entecavir as
monotherapy for short duration
discontinue treatment after two consective
tests 4 weeks apart confirm patient has
cleared HBSAg
Copyright @ Forever Medic Online Pvt. Ltd
9. Email: enquiry@medicyatra.com
Treatment
RCT of lamivudine to treat acute Hep B:
71 pts. 31 pts received lamivudine 100 mg
daily for 3 mo (group 1), 40 received placebo
(group 2)
At wk 4, HBV DNA levels significantly lower in
treated group (p=0.037), but thereafter levels
were similar
Improvement in serum bili, ALT, INR values
similar in 2 groups
Hepatology. 2007 Jan;45(1):97-101
Copyright @ Forever Medic Online Pvt. Ltd
10. Email: enquiry@medicyatra.com
Treatment
After 1yr, 93.5% of pts in lamivudine group and
96.7% of pts in placebo group lost HBsAg
After 1yr, 21 pts (67.7%) in treatment group and
34 pts (85%) in placebo developed protective
anti-HBs titers
No deaths in either group
Conclusion: No significant biochemical or clinical
improvement with lamivudine compared to
placebo
Hepatology. 2007 Jan;45(1):97-101
Copyright @ Forever Medic Online Pvt. Ltd
11. Email: enquiry@medicyatra.com
Consider Treatment in:
Pts w/ a coagulopathy (INR >1.5)
Those w/ a protracted course (persistent
symptoms or marked jaundice w/ bilirubin >10
mg/dl for more than four weeks)
Pts with fulminant hepatitis B (to reduce the
likelihood of reinfection post-liver transplant)
Immunocompromised patients
Those with concomitant infection with hepatitis C
or D virus or preexisting liver disease
Elderly patients
Copyright @ Forever Medic Online Pvt. Ltd
12. Email: enquiry@medicyatra.com
Prevention
Hepatitis B
vaccination!
Series of three doses
at months 0, 1 to 2,
and then 6 to 12
In US, universal
vaccination of all
newborns is
recommended
Copyright @ Forever Medic Online Pvt. Ltd
13. Email: enquiry@medicyatra.com
Prevention
Vaccinate high risk
adults:
Healthcare workers
IV drug users
Household contacts of
people w/ Hep B
Pts w/ multiple sexual
partners
Men who have sex with
men
HD patients
Pts who require repeated
transfusions of blood
products
Pts w/ chronic liver disease
Copyright @ Forever Medic Online Pvt. Ltd
14. Email: enquiry@medicyatra.com
Efficacy
positive immune response is
defined as development of
anti-HBs at a titer of >10 IU/L
95% seroconversion in healthy
adults
Post-vaccination testing in
healthcare workers/HD pts/pts
who are at risk for recurrent
exposure 1-2 mos after
completion of vaccination.
Nonresponders complete a
second 3-dose vaccination
series
Copyright @ Forever Medic Online Pvt. Ltd
Notas del editor
Rate of progression in perinatally acquired infections is 90%, 20-50% for infections between age 1 and 5
Window period: The disappearance of HBsAg (hepatitis B surface antigen) is followed by the appearance of anti-HBs. In some patients, however, anti-HBs may not be detectable until after a window period of several weeks to months. At this time, when neither HBsAg nor anti-HBs can be detected, the serologic diagnosis may be made by the detection of IgM antibodies against hepatitis B core antigen (IgM anti-HBc).
Time course: development of encephalopathy within 8 weeks of the onset of symptoms, or within two weeks of developing jaundice. Liver failure is considered “subfulminant” if development of encephalopathy within 6 months but outside the 2 week/8 weeks. Case control study evaluated risk factors for a fulminant course in an outbreak among injection drug users. Compared with control patients, case patients were more likely to have used acetaminophen during their illness (p=.08) and had lost significantly more weight in the six months before illness, used more alcohol, and methamphetamine. Furthermore, all nine isolates were genotype D.
Efficacy decreases to 86% in 4 th decade, 47% in sixth decade. response rate is slightly lower in obese individuals, smokers, and men, and significantly lower in patients with cirrhosis or chronic renal failure, organ transplant recipients, children with celiac disease, and immunosuppressed patients.